Welcome!

News Feed Item

Broadridge Financial Solutions, VeriFone Systems, Gilead Sciences, Johnson & Johnson and Forest Laboratories highlighted as Zacks Bull and Bear of the Day

CHICAGO, Jan. 3, 2014 /PRNewswire/ -- Zacks Equity Research highlights Broadridge Financial Solutions (NYSE:BR-Free Report) as the Bull of the Day and VeriFone Systems (NYSE:PAY-Free Report)as the Bear of the Day. In addition, Zacks Equity Research provides analysis ontheGilead Sciences, Inc. (Nasdaq:GILD-Free Report), Johnson & Johnson (NYSE:JNJ-Free Report) and Forest Laboratories Inc. (NYSE:FRX-Free Report).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Here is a synopsis of all five stocks:

Bull of the Day:

Broadridge Financial Solutions (NYSE:BR-Free Report) is a provider of technology solutions including investor communications, securities processing and operations to banks, broker-dealers, mutual funds, and corporate issuers globally.

It is the former Brokerage Services division of ADP and was spun-off from ADP in 2007. The company has seen a compounded annual fee growth of 6% since it was spun-off.

BR processes 85% of all outstanding shares voted in the US and 72% of shares voted outside of the US.

Broadridge reported financial results for the first quarter of its fiscal year 2014 on November 7, 2013. Total Revenues increased 10% to $545 million from $496 million, primarily due to growth in net new business and by internal growth.

Non-GAAP Diluted earnings increased 117% to $0.39 per share, substantially ahead of the Zacks Consensus Estimate of $0.20 per share.

The management reaffirmed their full year guidance provided in August 2013--total revenue growth in the range of 2% to 4% and diluted earnings per share in the range of $2.00 to $2.10.

After excellent results and reaffirmation of guidance, analysts have increased their estimates for BR.

Zacks Consensus Estimate for the current and next fiscal year are now at $2.29 per share and $2.47 per share respectively, up from $2.06 per share and $2.26 per share, 60 days ago. Rising estimates sent BR to Zacks Rank # 1 (Strong Buy) on November 14, 2013.

Bear of the Day:

VeriFone Systems (NYSE:PAY-Free Report) is a provider of technology for electronic payment transactions and value-added services at the point of sale. Its customers are primarily global financial institutions, payment processors, petroleum companies, large retailers, government organizations and healthcare companies, as well as independent sales organizations. 

PAY reported the financial results for Q4 of the fiscal year ended October 31, 2013 on December 17, 2013. Net income for the quarter came in at $0.27 per share, compared to $0.76 per share a year ago. After including stock based compensation, the earnings were $0.13 per share, substantially short of the Zacks Consensus Estimate of $0.18 per share.

Gross margin contracted 310 basis points from the previous-year quarter and operating profit declined 70.4% mainly due to 11.5% year-over-year decline in revenues and 28.1% increase in operating expenses.

The management expects non-GAAP revenues to be in the range of $425.0 million–$430.0 million for the first quarter of fiscal 2014, almost unchanged from $429.0 million reported in the year-ago quarter.

Management expects first-quarter non-GAAP earnings to be $0.26 cents per share, down from $0.40 per share in the year-ago quarter.

Additional content:

Bullish on Gilead

Gilead Sciences, Inc. (Nasdaq:GILD-Free Report) had a very successful 2013 driven by its strong product portfolio. The biopharmaceutical company ended the year on a high with its blockbuster hopeful, Sovaldi, gaining U.S. approval for treating patients suffering from chronic hepatitis C virus (HCV).

Sovaldi, with its high cure rates, a short treatment period and reduction/elimination of the need for interferon injections, has the potential to change the treatment paradigm in the HCV space. The approval has been highly welcomed by HCV patients, many of whom have postponed their treatments waiting for a better therapy like Sovaldi to gain approval. We expect uptake in Sovaldi sales to be rapid, given its broad label and the pent-up demand for new HCV therapies.

The U.S. approval for Sovaldi comes a few weeks after the clearance of Johnson & Johnson's (NYSE:JNJ-Free Report) Olysio in combination with peg-IFN and ribavirin for treating chronic HCV patients.

The European approval of Sovaldi is also on track with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending its approval in the EU in Nov 2013. The positive opinion by the CHMP will be reviewed by the European Commission, which will issue final opinion on whether to approve the HCV candidate in the EU.

Other newly launched drugs like HIV therapies Complera/Eviplera (launched in 2011) and Stribild (launched in 2012) also performed very well during 2013. These drugs are expected to continue their strong performance in 2014 as well. In Dec 2013, Complera/Eviplera's label was expanded. Complera can now replace the existing antiretroviral treatment regimen in HIV infected adults. This should boost the sales potential of the drug further. The European approval of HIV drug Vitekta (elvitegravir) in Nov 2013 is another positive for Gilead.

Apart from the strong product portfolio, Gilead boasts of a robust pipeline. One of the most interesting candidates at Gilead is idelalisib (formerly GS-1101). The candidate, added to Gilead's pipeline through its acquisition of Calistoga Pharmaceuticals in 2011, is being developed for multiple indications.

At the annual meeting of the American Society of Hematology (ASH) in Dec 2013, Gilead presented encouraging data on the candidate from a phase II study (101-09: n=125) in the indolent non-Hodgkin's lymphoma (iNHL) indication, for which Gilead is seeking U.S. approval. Gilead also intends to seek approval for idelalisib in the chronic lymphocytic leukemia (CLL) indication and is in discussions with the FDA regarding the same. Idelalisib is under review in the EU in the CLL as well as iNHL indications. With the acceptance of Gilead's request for accelerated assessment by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), idelalisib is expected to be available in the EU in the latter half of 2014 (assuming approval).

Idelalisib on approval will augment Gilead's top line further. Another promising candidate in Gilead's pipeline is GS-9973. Encouraging interim data on the candidate from a phase II study was also presented at the ASH in patients with relapsed or refractory CLL or NHL. The successful development and subsequent commercialization of the pipeline candidates would boost Gilead's top line further.

In view of the above positives, we expect the company to perform well in 2014 as well. Forest Laboratories Inc. (NYSE:FRX-Free Report) carries a Zacks Rank #1 (Strong Buy).

Get today's Zacks #1 Stock of the Day with your free subscription to Profit from the Pros newsletter:

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Click here to subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on BR - FREE

Get the full Report on PAY - FREE

Get the full Report on GILD - FREE

Get the full Report on JNJ - FREE

Get the full Report on FRX - FREE

Follow us on Twitter:  http://twitter.com/zacksresearch

Join us on Facebook:  http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

SOURCE Zacks Investment Research, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
In the first article of this three-part series on hybrid cloud security, we discussed the Shared Responsibility Model and examined how the most common attack strategies persist, are amplified, or are mitigated as assets move from data centers to the cloud. Today, we’ll look at some of the unique security challenges that are introduced by public cloud environments. While cloud computing delivers many operational, cost-saving and security benefits, it takes place in a public, shared and on-demand ...
Both SaaS vendors and SaaS buyers are going “all-in” to hyperscale IaaS platforms such as AWS, which is disrupting the SaaS value proposition. Why should the enterprise SaaS consumer pay for the SaaS service if their data is resident in adjacent AWS S3 buckets? If both SaaS sellers and buyers are using the same cloud tools, automation and pay-per-transaction model offered by IaaS platforms, then why not host the “shrink-wrapped” software in the customers’ cloud? Further, serverless computing, cl...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin, ...
Information technology (IT) advances are transforming the way we innovate in business, thereby disrupting the old guard and their predictable status-quo. It’s creating global market turbulence. Industries are converging, and new opportunities and threats are emerging, like never before. So, how are savvy chief information officers (CIOs) leading this transition? Back in 2015, the IBM Institute for Business Value conducted a market study that included the findings from over 1,800 CIO interviews ...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
China Unicom exhibit at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE FDD, TD-LTE), fixed-line broadband, ICT, data communica...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Zerto exhibited at SYS-CON's 18th International Cloud Expo®, which took place at the Javits Center in New York City, NY, in June 2016. Zerto is committed to keeping enterprise and cloud IT running 24/7 by providing innovative, simple, reliable and scalable business continuity software solutions. Through the Zerto Cloud Continuity Platform™, organizations can seamlessly move and protect virtualized workloads between public, private and hybrid clouds. The company’s flagship product, Zerto Virtual...
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, will present an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He will expound on the industry issues he frequently came up against as an analyst, and...